ATHA (Athira Pharma Corp) יחס שווי שוק לשווי בספרים

Athira Pharma, Inc. (ATHA) is developing methods to combat Alzheimer's disease, leveraging patents that will ensure minimal costs during mass production. Test robotization and automated molecule discovery are accelerating scientific progress. This price chart illustrates the asset's dynamics, where the indicator stands at 0.99. However, a funding shortage and the risk of failure in early-stage research are exerting significant pressure on the stock price.

The indicator is calculated as the quotient of current market capitalization divided by the amount of equity. This metric determines the degree of asset overvaluation or the level of discount to their book value. For Athira Pharma, Inc. (ATHA), this is critical, as the revision of the R&D strategy following failures in Alzheimer's therapy undermines confidence in the cost of capital. By analyzing the price-to-book ratio, an investor can identify the real risk of asset impairment.